Recovery and survival of platelet concentrates in plasma and in 3 additive solutions - RaSPAS study

Sanquin Bloedbank0 个研究点目标入组 25 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•* Age * 18 years.
•* Expected to require at least one platelet transfusion.
•* Signed informed consent.
•* Are hospitalized.
•* Clinically stable, i.e. no active bleeding, no fever, or other reasons for increased platelet consumption.
•* Have acute leukemia or MDS (myelodysplastic syndrome).

•* Micro-angiopathic thrombocytopenia (TTP, HUS) and ITP.
•* Bleeding greater than grade 2 at time of inclusion. If the patient has been treated for the bleeding complication, the patient can be included in the study 1 week after the last intervention that was used to stop the bleeding. Pre-existing skin bleeds (bruises) greater than 2.5 cm will not be included in judgment of the WHO bleeding grade at the time of assessment of eligibility or at the time of inclusion.
•* Transfusions within 1 week after ATG.
•* Known immunological refractoriness to platelet transfusions. Refractoriness may be known to the treating physician by either HLA/HPA antibody screening, or by earlier poor responses to platelet responses.
•* HLA- and/or HPA-allo immunization and/or clinical relevant auto-antibodies.
•* Indications to use platelet concentrates with specific characteristics/modifications (for example, volume reduced platelets, HLA matched platelets, etc).
•* Pregnancy (or lactating).

发起方

Sanquin Bloedbank